RxDoctor Payments Data

Porscha Branch

Family · Texarkana, ARNPI 1104316819

Payments from drug & device makers

$1,251in general payments, 2019–2025

Across 68 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$312
  • AbbVie$221
  • Otsuka America Pharmaceutical, Inc.$190
  • Alkermes, Inc.$147
  • Abbott$126
  • Neurocrine Biosciences, Inc.$40
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$1,251100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,251 in reported general payments places this provider in the 70th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$489
Medicare patients
16
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$110,983
MounjaroTirzepatide47$57,237
EliquisApixaban40$30,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$21,335
FarxigaDapagliflozin Propanediol14$18,774
JardianceEmpagliflozin17$16,498
SymbicortBudesonide/Formoterol Fumarate16$6,914
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,147
Gabapentin125$2,644
Albuterol Sulfate HfaAlbuterol Sulfate70$2,106
Losartan Potassium170$1,305
Tizanidine Hcl56$1,199
Atorvastatin Calcium151$1,105
Amlodipine Besylate239$1,012
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic14$816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$110,98383 claims
Lilly USA, LLCMounjaro$22$57,23747 claims
GSKTrelegy Ellipta$28$21,33523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,103 family providers in Arkansas.

Other family in Texarkana

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →